Contents

SynopsisCodesLook ForDiagnostic PearlsDifferential Diagnosis & PitfallsBest TestsManagement PearlsTherapyDrug Reaction DataReferences

View all Images (18)

Cholesterol emboli
Other Resources UpToDate PubMed

Cholesterol emboli

Contributors: Erin X. Wei MD, Susan Burgin MD, Paritosh Prasad MD
Other Resources UpToDate PubMed

Synopsis

Atherosclerotic plaques of the aortic arch complicating hyperlipidemic states are a significant etiologic cause of thromboembolic disease. Thomboembolism occurs when a thrombus associated with an aortic atherosclerotic plaque dislodges, often in the context of atherosclerotic plaque rupture. Thrombi tend to lodge in large-to-medium arteries and commonly present as an acute ischemic stroke or transient ischemic attack. Other presentations include acute limb, bowel, and visceral (kidney, spleen, etc) ischemia.

Cholesterol embolization, on the other hand, refers to the release of cholesterol crystals into circulation following plaque rupture or disruption. These crystals result in occlusion of smaller vessels, generally involving arterioles (less than 200 micrometers diameter). The crystals occlude arterioles by 2 mechanisms. First, the crystals physically block smaller arterioles. Second, they activate complement, inducing an inflammatory response, which leads to adventitial fibrosis and obliteration of the vessel lumen. Because emboli are small and numerous, this leads to multisystem disease.

The classical clinical triad attributed to cholesterol embolization includes the development of livedo reticularis, acute renal failure, and peripheral eosinophilia, but in clinical practice, the presentation can be varied depending on the location of the source plaque and the degree and location of embolization. For example, ascending arch emboli generally involve the head, eyes, and upper extremities, while those involving the descending arch more commonly affect the abdominal viscera and lower extremities.

The term cutaneous cholesterol embolism signifies involvement of the skin due to cholesterol embolism. It is also referred to as cholesterol embolization syndrome, lower extremity atheromatous emboli syndrome, and purple or blue toe syndrome.

Cholesterol emboli can occur as a result of invasive coronary procedures such as major vessel surgery, angiography, angioplasty, or following anticoagulant or thrombolytic therapy. Anticoagulants and thrombolytics act by targeting the breakdown of the protective clot that stabilizes an ulcerated atheromatous lesion, thereby releasing cholesterol crystals into the bloodstream. Heparin, warfarin sodium, and streptokinase have been reported as causative agents. Formation of cholesterol emboli may also follow cardiopulmonary resuscitation. Rarely, cholesterol embolization can occur spontaneously without any preceding intervention.

Cholesterol embolization is more common in men, typically aged 60-70 years.

Risk factors:
  • Extensive atherosclerosis
  • Systemic hypertension
  • Diabetes mellitus
Precipitating factors:
  • Angiography
  • Anticoagulation
  • Thrombolysis
  • Vascular intervention such as angiography, heart catheterization, coronary artery bypass grafting, and percutaneous transluminal coronary angioplasty.
In addition to the cutaneous manifestations of the disease, patients will also exhibit the general physical signs of fever, weight loss, tachycardia, and hypertension. Other signs and symptoms will vary according to which system is involved. Cardiovascular system involvement may produce congestive heart failure or a myocardial infarction. If the central nervous system is involved, then stroke, paraplegia, confusion, or delirium may result. Renal involvement occurs quite often, resulting in acute renal failure. Microhematuria can be noted on urinalysis.

The prognosis is poor, as renal failure is progressive, frequently requiring dialysis permanently, but occasionally renal function will stabilize or improve. Ischemic changes of limbs often lead to gangrene and subsequent amputation. Death most often occurs from cardiovascular causes, and the mortality rate stands at 78%, as seen in one study.

Codes

ICD10CM:
I75.89 – Atheroembolism of other site

SNOMEDCT:
236489002 – Cholesterol embolus syndrome

Look For

Subscription Required

Diagnostic Pearls

Subscription Required

Differential Diagnosis & Pitfalls

There is a time lag of about 1-4 weeks between the causative interventional procedure and onset of the disease, making diagnosis difficult.

The differential diagnosis of cutaneous findings includes the following:

Best Tests

Subscription Required

Management Pearls

Subscription Required

Therapy

Subscription Required

Drug Reaction Data

Below is a list of drugs with literature evidence indicating an adverse association with this diagnosis. The list is continually updated through ongoing research and new medication approvals. Click on Citations to sort by number of citations or click on Medication to sort the medications alphabetically.

Subscription Required

References

Subscription Required

Last Reviewed:04/23/2022
Last Updated:05/05/2022
Copyright © 2022 VisualDx®. All rights reserved.
Cholesterol emboli
A medical illustration showing key findings of Cholesterol emboli : Fever, Cyanosis, Gangrene, Tachycardia, Toes, Skin ulceration, Peripheral eosinophilia
Clinical image of Cholesterol emboli - imageId=227719. Click to open in gallery.  caption: 'Retiform eschars with surrounding retiform violaceous patches and plaques on the buttocks.'
Retiform eschars with surrounding retiform violaceous patches and plaques on the buttocks.
Copyright © 2022 VisualDx®. All rights reserved.